Bio-Techne (TECH) announced a strategic partnership to distribute Spear Bio’s next-generation ultrasensitive immunoassays, enabling the detection of low-abundance biomarkers in neurology. Under the agreement, Bio-Techne will distribute Spear Bio’s ultrasensitive immunoassays for challenging low-abundance biomarkers, including key Alzheimer’s disease biomarkers such as phosphorylated tau 217, GFAP, neurofilament light, and phosphorylated tau 231. The initial offering will focus on key biomarkers supporting translational research in Alzheimer’s disease. This partnership follows Bio-Techne’s participation in Spear Bio’s $45M Series A funding round in 2024. Spear Bio’s Successive Proximity Extension Amplification Reaction platform, based on technology licensed from Harvard University, and amplified using conventional qPCR instrumentation, offers sensitivity two to three orders of magnitude higher than current immunoassay platforms.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TECH:
- Bio-Techne initiated with a Buy at TD Cowen
- Bio-Techne: Undervalued Stock with Strong Growth Potential and Margin Expansion Opportunities
- Bio-Techne, USP collaborate to develop monoclonal antibody and gene therapy
- Airbnb, Zscaler downgraded: Wall Street’s top analyst calls
- Bio-Techne price target lowered to $65 from $90 at Argus